New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Immunology Letters

• Publication date

  2011-01-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.imlet.2010.09.022PMID 20951741
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype

  2010cited by this paper
• T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.

  2010cited by this paper
• Cutaneous B‐cell lymphomas: facts and open issues

  2004cited by this paper
• Diagnostic principles and new developments in primary cutaneous B-cell lymphomas.

  2004cited by this paper
• Antigen unmasking on formalin‐fixed, paraffin‐embedded tissue sections

  1993cited by this paper
• Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

  1984cited by this paper

• Interplay Between Key Molecular Signaling Pathways and Immune Players Following Brain Irradiation

  2025cites this paper
• Immune Checkpoint Inhibitors Impact Fertility: A Review.

  2025cites this paper
• Immunotherapy in gestational trophoblastic neoplasia: advances and future directions

  2025cites this paper
• Nanoengineered Platform-Based Microenvironment-Triggered Immunotherapy in Cancer Treatment.

  2024cites this paper
• SLAM Family Receptors in B Cell Chronic Lymphoproliferative Disorders

  2024cites this paper
• The interplay between metabolic adaptations and diet in cancer immunotherapy.

  2024cites this paper
• The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review

  2024cites this paper
• Design, synthesis, and antitumor activity evaluation of 1,2,3-triazole derivatives as potent PD-1/PD-L1 inhibitors.

  2024cites this paper
• Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non–small cell lung cancer

  2024cites this paper
• Multi-targeted immunotherapeutics to treat B cell malignancies.

  2023cites this paper
• Soluble Programmed Death-Ligand 1 (sPD-L1) as a Promising Marker for Head and Neck Squamous Cell Carcinoma: Correlations With Clinical and Demographic Characteristics

  2023cites this paper
• Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer.

  2023cites this paper
• CD70 and PD‐L1 (CD274) co‐expression predicts poor clinical outcomes in patients with pleural mesothelioma

  2023cites this paper
• Progress of immunotherapies in gestational trophoblastic neoplasms

  2023cites this paper
• Adipocyte glucocorticoid receptor inhibits immune regulatory genes to maintain immune cell homeostasis in adipose tissue.

  2023cites this paper
• Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model

  2022cites this paper
• New Immunometabolic Strategy Based on Cell Type-Specific Metabolic Reprogramming in the Tumor Immune Microenvironment

  2022cites this paper
• How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC.

  2022cites this paper
• Paraneoplastic Neurological Syndromes: Transitioning Between the Old and the New

  2022cites this paper
• Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma

  2022cites this paper
• Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future

  2022cites this paper
• Genetic evidence for the causal association between programmed death-ligand 1 and lung cancer

  2021cites this paper
• Fractional Laser Treatment Boosts Systemic Anti-Tumor Immunity in Combination with OX40 Agonist and PD-1 Blockade

  2021cites this paper
• Activated B-cells and Plasma cells are Resistant to Radiation Therapy.

  2021cites this paper
• ASSESSMENT OF STROMAL AND INTRA-EPITHELIAL TUMOR INFILTRATING LYMPHOCYTES IN COLORECTAL CARCINOMA AT ARMED FORCES INSTITUTE OF PATHOLOGY

  2021cites this paper
• The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy

  2021cites this paper
• A snapshot of the PD-1/PD-L1 pathway

  2021cites this paper
• CMAR_A_269773 9389..9403

  2020cites this paper
• The Recent Advances of Anti-PD-1/PD-L1 Immunotherapy

  2020cites this paper
• Cancer Immunology: A Translational Medicine Context

  2020cites this paper
• Resistance to Checkpoint Inhibition in Cancer Immunotherapy

  2020cites this paper
• Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer

  2020cites this paper
• CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness

  2020cites this paper
• Immunosenescence and Cancer Immunotherapy at Old Age: Basics

  2020cites this paper
• Application and Prospects of Molecular Imaging in Immunotherapy

  2020cites this paper
• Overcoming Cancer Tolerance with Immune Checkpoint Blockade

  2020cites this paper
• Integrated immune gene expression signature and molecular classification in gastric cancer: New insights

  2020cites this paper
• Circulating PD-1 mRNA in Peripheral Blood is a Potential Biomarker for Predicting Survival of Breast Cancer Patients

  2020cites this paper
• Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection

  2020cites this paper
• Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations

  2019cites this paper
• Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma

  2019cites this paper
• Promising approaches in cancer immunotherapy.

  2019cites this paper
• Expression and prognostic significance of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma.

  2019cites this paper
• Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules.

  2019cites this paper
• Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia

  2019cites this paper
• SLAMF1/CD150 in hematologic malignancies: Silent marker or active player?

  2019cites this paper
• INHIBITION OF UROTHELIAL CARCINOMA BY TYPE I INTERFERON ACTIVATION OF THE INNATE AND ADAPTIVE IMMUNE RESPONSE

  2019cites this paper
• Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

  2019cites this paper
• Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status

  2019influential citation
• Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients

  2019cites this paper
• Cancer immunotherapy: present scenarios and the future of immunotherapy

  2019cites this paper
• Prognostic role of tumour-infiltrating T lymphocytes in stage IIA (T3N0) colon cancer: A broad methodological study in a fairly homogeneous population.

  2019cites this paper
• Signaling lymphocytic activation molecule family-1 (CD150) expression as a prognostic indicator in patients with chronic lymphocytic leukemia

  2018cites this paper
• The progress of PD-1 inhibitors in small-cell lung cancer

  2018cites this paper
• Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.

  2018cites this paper
• PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments

  2018cites this paper
• The expression of PD-L1 in patients with castrate prostate cancer treated with enzalutamide.

  2018cites this paper
• Structure-Function Analysis of Immune Checkpoint Receptors to Guide Emerging Anticancer Immunotherapy.

  2018cites this paper
• Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors

  2018cites this paper
• Molecular Markers for Colorectal Cancer.

  2017cites this paper
• Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas

  2017cites this paper
• Immunotherapy comes of age: Immune aging & checkpoint inhibitors.

  2017cites this paper
• KLHL6 Is Preferentially Expressed in Germinal Center–Derived B-Cell Lymphomas

  2017cites this paper
• The prognostic effect of neoadjuvant chemoradiotherapy on the change of PD-L1 expression in patients with locally advanced rectal adenocarcinoma.

  2017cites this paper
• The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling

  2017cites this paper
• Immunotherapy of cancers comes of age

  2017cites this paper
• The role of G protein-coupled receptors in lymphoid malignancies.

  2017cites this paper
• PD‐L1 expression is mainly regulated by interferon gamma associated with JAK‐STAT pathway in gastric cancer

  2017cites this paper
• Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-α

  2017cites this paper
• Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.

  2017cites this paper
• The swinging pendulum of cancer immunotherapy personalization.

  2017cites this paper
• Pembrolizumab's non-cross resistance mechanism of action successfully overthrown ipilimumab.

  2017cites this paper
• Pembrolizumab in the treatment of advanced urothelial cancer.

  2017cites this paper
• Stromal and intraepithelial tumor-infiltrating lymphocytes in colorectal carcinoma

  2017cites this paper
• Checkpoint Blockade Immunotherapy for Glioblastoma

  2017cites this paper
• B lymphocytes and cancer: a love-hate relationship.

  2016cites this paper
• Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors

  2016cites this paper
• PD-1 EXPRESSION AS DIAGNOSTIC MARKER FOR PRIMARY CUTANEOUS CD4+ SMALL/MEDIUM-SIZED PLEOMORPHIC T-CELL LYMPHOMA AND CUTANEOUS PSEUDO-T-CELL LYMPHOMA

  2016cites this paper
• Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer

  2016cites this paper
• Differential expression of CD150/SLAMF1 in normal and malignant B cells on the different stages of maturation.

  2016cites this paper
• Immunosuppression in liver tumors: opening the portal to effective immunotherapy

  2016cites this paper
• Checkpoint Blockade for the Treatment of Advanced Melanoma.

  2016cites this paper
• PROGRAMMED DEATH-1 EXPRESSION IN CUTANEOUS B-CELL LYMPHOMA 6

  2016cites this paper
• Targeting immune checkpoints in malignant glioma

  2016cites this paper
• Assessment of combined vaccination and immune modulation as an anti-tumour therapy

  2016cites this paper
• Blocking Immunosuppressive Factors and Taking Advantage of the Nutrient Supply Within the Tumor Microenvironment: Pathways to Achieve Improved Cancer Immunotherapeutic Efficacy for Patients With Metastatic Melanoma

  2016cites this paper
• Immune checkpoint inhibition in lymphoid disease

  2015cites this paper
• B7家族共刺激分子在血液系统恶性肿瘤中的研究进展

  2015cites this paper
• A Genomic Approach to the Identity, Clonal Diversity, and Clinical Import of Tumor-infiltrating Lymphocytes in Human Cancers

  2015cites this paper
• Patterns of T cell co-stimulation and co-inhibition in tumor microenvironment conditions, in vitro

  2015cites this paper
• Current status of checkpoint inhibitors in lymphoma

  2015cites this paper
• Nivolumab in the treatment of advanced melanoma

  2015cites this paper
• Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma.

  2015cites this paper
• Immune Checkpoint Blockade in Cancer Therapy.

  2015cites this paper
• Anti-PD-1 therapy in melanoma.

  2015cites this paper
• Mechanisms of action of therapeutic antibodies for cancer.

  2015cites this paper
• Immunotherapy for lung cancer: for whom the bell tolls?

  2015cites this paper
• Primary Cutaneous Lymphomas

  2014cites this paper
• Programmed death‐1 expression in cutaneous B‐cell lymphoma

  2014cites this paper
• Mechanism of action of immunotherapy.

  2014cites this paper